Safety, effectiveness and haemodynamic performance of a new stented aortic valve bioprosthesis†
Authors:
- Robert J.M. KlautzRKRobert J.M. Klautz
- on behalf of the PERIGON InvestigatorsOIon behalf of the PERIGON Investigators
Open Access
- 4 May 2017
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 52 (3) , 425-431
Abstract
We assessed the safety, effectiveness and haemodynamic performance of a new bovine stented aortic valve bioprosthesis (Avalus™). The PERIGON Pivotal Trial is a prospective, non-randomized, multicentre study. Subjects had symptomatic moderate or severe aortic stenosis or chronic, severe aortic regurgitation. Death, valve-related adverse events (AEs), functional recovery and haemodynamic performance were assessed at discharge, 3–6 months and 1 year. The primary analysis compared ‘late’ (>30 days post-implant) linearized rates of valve-related thromboembolism, thrombosis, all and major haemorrhage, all and major paravalvular leak (PVL) and endocarditis after implantation with objective performance criteria (OPC) for AEs, in accordance with EN ISO 5840:2009. We hypothesized that the upper 95% confidence bounds of the true linearized AE rates would be ≥ 2 × OPC; rejection of the null hypothesis would demonstrate that these rates were below acceptable rates. The analysis was required to include at least 150 patients followed to 1 year and 400 valve-years. Kaplan–Meier survival analysis was also performed. Total number of valve-years was 459.5 (n = 686). Linearized rates were n = 270) was 96.4%. Patients showed good functional recovery, and haemodynamic performance was within expected range. This analysis demonstrated a good safety profile and clinical effectiveness of the Avalus valve except for bleeding rates. The linearized rates of all and major haemorrhage may be related to long-term anticoagulation for non-valvular indications and the length of follow-up of this cohort. NCT02088554 (www.clinicaltrials.gov).Keywords
This publication has 15 references indexed in Scilit:
- Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve StenosisJACC, 2015
- Matched Comparison of Two Different Biological Prostheses for Complete Supra-annular Aortic Valve ReplacementThe Thoracic and Cardiovascular Surgeon, 2015
- The new St Jude Trifecta versus Carpentier-Edwards Perimount Magna and Magna Ease aortic bioprosthesis: Is there a hemodynamic superiority?The Journal of Thoracic and Cardiovascular Surgery, 2014
- The St Jude Medical Trifecta aortic pericardial valve: Results from a global, multicenter, prospective clinical studyThe Journal of Thoracic and Cardiovascular Surgery, 2014
- Trends in Aortic Valve Replacement for Elderly Patients in the United States, 1999-2011JAMA, 2013
- Prosthesis-Patient Mismatch: An UpdateCurrent Cardiology Reports, 2011
- Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: Changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National DatabaseThe Journal of Thoracic and Cardiovascular Surgery, 2009
- Guidelines for reporting mortality and morbidity after cardiac valve interventionsEuropean Journal of Cardio-Thoracic Surgery, 2008
- Comparison of different anticalcification treatments for stentless bioprosthesesThe Annals of Thoracic Surgery, 1998
- Sample size requirements for evaluating heart valves with constant risk events.1994